Q1 2024 New Drug Report (January - March)

Posted on by myMatrixx
MyMatrixx PharmaWatch Clinical Updates

The following table represents a summary of prescription drug changes in the market from Q1 2024 (January through March) that may potentially be seen in workers' compensation. These could be new drug approvals, new generics, withdrawals and discontinuations of certain products, as well as near-term pipeline products and patent expirations. There may be other labeled or off-label uses for these products that may or may not be supported by medical treatment guidelines.

In some cases, there may not be an exact date listed, so the assumption would be that the approval or patent expiration would be at some point during the listed month, quarter or year. For discontinued medications, dispensing may still continue until pharmacies have exhausted their existing supply. Anticipated approval dates and availability of generics are subject to final FDA approval. Please note that these lists are not all-inclusive.

If you have any questions, please contact your Clinical Account Executive or another member of your account team.

Workers’ Compensation Prescription Drug Updates

Recent Generic Launches
Brand Name (Generic Name)Indication/UseLaunch Date
Indocin® (indomethacin)Pain/InflammationJanuary 12, 2024
Gralise® (gabapentin once daily) 300 mg and 600 mg tabletPain/InflammationJanuary 29, 2024

Discontinuation and Withdrawals
MedicationIndication/UseDiscontinuation Date
Zorvolex™ (diclofenac capsule)Pain/InflammationJanuary 2, 2024
Oxaydo® (oxycodone tablet)PainJanuary 30, 2024

New Drug Pipeline
MedicationIndication/UseAnticipated Approval
Livervant (diazepam film)SeizuresApril 28, 2024
naloxone intranasalOpioid OverdoseJuly 15, 2024
midomafetaminePost-Traumatic Stress DisorderAugust 11, 2024
Neffy (epinephrine nasal spray)AnaphylaxisOctober 2, 2024
Omlyclo (omalizumab biosimilar)AsthmaMarch 10, 2025

Patent Expirations
Brand Name (Generic Name)Indication/UsePatient Expiration
Prialt® (ziconotide intrathecal)PainOctober 1, 2024
Flovent HFA (fluticasone propionate)Asthma2024
Isentress® 400 mg (raltegravir)HIV/Post-Exposure Prophylaxis (PEP)2024
Rayos® (prednisone delayed release)Inflammation2024